322. Hemophilia A and B: Clinical and Epidemiological: Poster II

Evaluating the safety and tolerability of switching from emicizumab to fitusiran prophylaxis in adult males with severe hemophilia A with or without inhibitors SWITCH study a trial in progress

Pregnancy and delivery outcomes in women with Hemophilia A and B A multicenter cohort study from the Italian association of haemophilia centers

Genetic landscape of Hemophilia A in Korea Insights from precision diagnosis in Hemophilia A

Updated meta analysis of inhibitor development in previously untreated patients with severe Hemophilia A Plasma derived versus recombinant FVIII products

Concizumab plasma concentration measurements for personalized dose adjustment in patients with Hemophilia A B with and without inhibitors Data from the Phase 3 explorer7 and explorer8 studies

A risk based scoring approach to individualize prophylaxis in patients with Hemophilia A Results from the predict study

Management of breakthrough bleeds in participants with hemophilia Α or Β without inhibitors receiving marstacimab prophylaxis in the phase 3 BASIS study

A FXIa modified clot waveform analysis for estimation of factor VIII level and emicizumab concentration in hemophilia A

Outcomes of arthroplasty in persons with hemophilia A survey of Medicare data

Real world factor VIII trough levels of severe type people with Hemophilia A PwHA on efanesoctocog alfa prophylaxis Interpersonal variation clinical correlates and predictors

RESHAPE A non interventional study of real world treatment patterns and outcomes across age groups in people with severe hemophilia A in Latin America Eastern Europe Africa Asia and the Middle East

Ex vivo evaluation of the procoagulant effect of NXT007 prophylaxis in people with Hemophilia A without factor VIII inhibitors Phase I II study NXTAGE